Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic …
PM Ellis, N Coakley, R Feld, S Kuruvilla, YC Ung - Current oncology, 2015 - mdpi.com
… gefitinib, erlotinib, afatinib, dacomitinib, or icotinib had a higher probability of experiencing
an event; conversely, a hr less than 1.0 suggests that patients receiving erlotinib or gefitinib …
an event; conversely, a hr less than 1.0 suggests that patients receiving erlotinib or gefitinib …
[HTML][HTML] Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non‑small cell lung cancer: A network meta‑analysis
Y Liu, Y Zhang, G Feng, Q Niu… - Experimental and …, 2017 - spandidos-publications.com
… compared with gefitinib and icotinib (P<0.05). In conclusion, gefitinib, erlotinib and icotinib
had … However, gefitinib resulted in a lower frequency of fatigue, and nausea and vomiting, …
had … However, gefitinib resulted in a lower frequency of fatigue, and nausea and vomiting, …
[HTML][HTML] Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
Q He, J Liu, X Cai, M He, C Li, H Liang… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
… gefitinib vs. chemotherapy in EGFR-mutant patients with completely resected NSCLC confirmed
that adjuvant gefitinib … EGFR-TKIs included icotinib, erlotinib and gefitinib. Previous trial …
that adjuvant gefitinib … EGFR-TKIs included icotinib, erlotinib and gefitinib. Previous trial …
[HTML][HTML] Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations
W Liang, X Wu, W Fang, Y Zhao, Y Yang, Z Hu, C Xue… - PloS one, 2014 - journals.plos.org
… indicated that erlotinib, gefitinib, afatinib and icotinib shared … Erlotinib and afatinib revealed
potentially better efficacy but significant higher toxicities compared with gefitinib and icotinib…
potentially better efficacy but significant higher toxicities compared with gefitinib and icotinib…
[HTML][HTML] Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: a direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude …
J Tan, M Li, W Zhong, C Hu, Q Gu, Y Xie - Oncotarget, 2017 - ncbi.nlm.nih.gov
… , we found that gefitinib penetrated the blood-… erlotinib or icotinib in a nude mouse model.
The 1-h ratio of brain metastases to plasma concentration for gefitinib, erlotinib, and icotinib …
The 1-h ratio of brain metastases to plasma concentration for gefitinib, erlotinib, and icotinib …
Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung …
X Xiong, Y Zhang, Z Wang, C Zhou, P Yang, X Du… - Clinica Chimica …, 2022 - Elsevier
… A new method for the simultaneous analysis of five EGFR-TKIs (afatinib, erlotinib, gefitinib,
icotinib and osimertinib) and their metabolites in human plasma samples was developed and …
icotinib and osimertinib) and their metabolites in human plasma samples was developed and …
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
Y Shi, L Zhang, X Liu, C Zhou, S Zhang, D Wang… - The lancet …, 2013 - thelancet.com
… Gefitinib and erlotinib are EGFR TKIs that were shown to greatly improve clinical outcomes
and safety when compared with chemotherapy or placebo in second-line or further-line …
and safety when compared with chemotherapy or placebo in second-line or further-line …
Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer
F Tan, Y Shi, Y Wang, L Ding, X Yuan, Y Sun - Future Oncology, 2015 - Taylor & Francis
… (ICOGEN), which showed icotinib is noninferior to gefitinib. This review will discuss the role
of … In this study, the quality-adjusted life years (QALYs) for icotinib, gefitinib and erlotinib were …
of … In this study, the quality-adjusted life years (QALYs) for icotinib, gefitinib and erlotinib were …
Efficacy of icotinib and gefitinib in advanced lung adenocarcinoma with EGFR mutation
H CUI, J GUAN, G LIAO, P LIU… - … OF CHINESE PLA …, 2015 - xuebao.301hospital.com.cn
… icotinib group and gefitinib group randomly, and patients in icotinib group were treated
with icotinib three times a day by 125 mg, patients in gefitinib group were treated with gefitinib …
with icotinib three times a day by 125 mg, patients in gefitinib group were treated with gefitinib …
[HTML][HTML] Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
K Liu, G Jiang, A Zhang, Z Li, J Jia - BMC cancer, 2020 - Springer
… icotinib arm and 2 in the gefitinib arm. These results indicated that icotinib was as efficacious
as gefitinib … is cheaper than any other targeted agents such as gefitinib, erlotinib and afatinib…
as gefitinib … is cheaper than any other targeted agents such as gefitinib, erlotinib and afatinib…